Gastric Volvulus Treatment Global Market Report 2024

The gastric volvulus treatment market size has grown strongly in recent years. It will grow from $25.6 billion in 2023 to $27.18 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historical period can be attributed to factors such as advancements in surgical techniques, enhanced diagnostic technologies, increased awareness and education, a rise in the adoption of minimally invasive procedures, and the influence of research and clinical studies.

The gastric volvulus treatment market size is expected to see strong growth in the next few years. It will grow to $34.63 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to regulatory changes and approvals, innovations in surgical procedures, the expanding geriatric population, the development of customized treatment plans, and the adoption of advanced imaging techniques. Major trends expected in the forecast period include the continued prominence of minimally invasive surgical techniques, a focus on awareness and early intervention, ongoing research in treatment modalities, the promotion of collaborative medical practices, and the increasing prevalence of customized treatment approaches.

The anticipated growth in the geriatric population is poised to drive the expansion of the gastric volvulus treatment market in the foreseeable future. The term 'geriatric population' pertains to individuals aged 65 and beyond, who are susceptible to various illnesses due to compromised immunity and advancing age. As gastric volvulus tends to occur in individuals over 50, the increasing number of elderly individuals is expected to be a significant factor propelling the market. According to America's Health Rankings in November 2022, the United States had over 55.8 million people aged 65 and above in 2021, constituting nearly 16.8% of the total population. Consequently, the growing geriatric population is a driving force behind the gastric volvulus treatment market.

The escalating incidence of gastrointestinal diseases is projected to be a key driver for the growth of the gastric volvulus treatment market in the coming years. Gastrointestinal diseases encompass a range of medical conditions affecting the internal structures of the gastrointestinal (GI) tract, including gastritis, inflammatory bowel disease, and gastric cancer. The holistic care provided during the treatment of gastric volvulus may involve strategies and considerations contributing to the overall health of the gastrointestinal system and its associated disorders. For example, as per Cancer Australia's data in September 2022, the projected number of new stomach cancer cases in Australia for 2022 is 2,572. This underscores the need for effective treatments in the face of increasing gastrointestinal diseases. Hence, the rising incidence of gastrointestinal diseases is a driving factor for the gastric volvulus treatment market.

Product innovations emerge as a prominent trend gaining traction in the gastric volvulus treatment market. Major companies in the market are introducing innovative products to maintain their competitive positions. For instance, in October 2023, Pfizer Inc., a pharmaceutical company based in the United States, announced the FDA approval of VELSIPITY (etrasimod) for people with moderate to severe active ulcerative colitis. This once-daily oral sphingosine-1-phosphate (S1P) receptor activator offers a positive benefit-risk profile, providing adults with an effective, steroid-free resolution through a convenient oral pill.

Companies operating in the gastric volvulus treatment market are focusing on product innovations such as digital radiology solutions to enhance radiologists' efficiency. A digital radiology solution involves leveraging digital technology in medical imaging for visualizing internal body structures and aiding in the diagnosis and management of conditions such as gastric volvulus through digital image capture and analysis. For instance, in February 2023, Carestream Health India Pvt. Ltd. launched the DRX Compass, a digital radiological solution designed for accuracy, convenience, and customization. This innovative solution empowers radiologists with heightened productivity and flexibility in configuring the system based on individual requirements.

In December 2021, Pfizer, a pharmaceutical and biotechnology corporation, acquired Arena Pharmaceuticals for $6.7 billion. This strategic acquisition aims to leverage Arena Pharmaceuticals' expertise in inflammation and immunology, contributing to Pfizer's innovation in developing potential therapies for patients dealing with immuno-inflammatory diseases, including gastrointestinal and dermatological conditions. Arena Pharmaceuticals is a U.S.-based company with a diverse portfolio of development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology.

Major companies operating in the gastric volvulus treatment market report are PAI Pharma, Sun Pharmaceutical Industries Ltd., ANI Pharmaceuticals Inc., Fresenius SE and Co. KGaA, Mayne Pharma Group Limited, Sawai Pharmaceutical Co.Ltd., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Tris Pharma Inc., Pfizer Inc., Mallinckrodt Pharmaceuticals, Mylan N.V., GlaxoSmithKline plc, Endo International plc, Vintage Labs, Zydus Group, Bayer AG, AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A., Novartis International AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Sanofi S.A., Celltrion Inc., HanAll Biopharma, AstraZeneca plc, ACROBiosystems Inc., Alomone Labs Ltd.

North America was the largest region in the gastric volvulus market in 2023. Asia-Pacific is expected to be the fastest-growing region in the gastric volvulus treatment market report during the forecast period. The regions covered in the gastric volvulus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric volvulus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of gastric volvulus treatment are organo-axial and mesentero-axial volvulus. Organo-axial volvulus occurs when the abdomen undergoes a 180-degree spin around its long axis, resulting in this condition. Treatment options include medication and surgery, with various routes of administration such as oral and parenteral. Distribution channels for these treatments include hospital pharmacies and retail pharmacies, serving purposes in hospitals, home healthcare, specialty clinics, and other healthcare settings.

The gastric volvulus treatment market research report is one of a series of new reports that provides gastric volvulus treatment market statistics, including gastric volvulus treatment industry global market size, regional shares, competitors with a gastric volvulus treatment market share, detailed gastric volvulus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the gastric volvulus treatment industry. This gastric volvulus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.